0:000:00
<p>Dr. John Sweetenham shares highlights from Day 5 of the 2025 ASCO Annual Meeting, including data from large trials in advanced malignant melanoma and mCSPC plus a new approach to first-line treatment for patients with multiple myeloma who are not transplant eligible.</p> <h2>Transcript</h2> <p class="MsoNormal"><span style= "font-size: 12.0pt; line-height: 107%;">Hello, I'm Dr. John Sweetenham, the host of the <em>ASCO Daily News</em> Podcast, with my takeaways on selected abstracts from Day 5 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode.</span></p> <p class="MsoNormal"><span style= "font-size: 12.0pt; line-height: 107%;">The selected abstracts from this final day of ASCO25 include important new data from large, randomized trials in patients with advanced malignant melanoma and patients with metastatic castration-sensitive prostate cancer, as well as a new approach to the first-line treatment of patients with multiple myeloma who ar...